Lirilumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameLirilumab
Drug Alias NameAnti-KIR (1-7F9)Anti-KIR monoclonal antibody - Innate PharmaBMS-986015IPH-2102IPH-2101 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionKiller cell immunoglobulin-like receptor 2DL1 antagonistsKiller cell immunoglobulin-like receptor 2DL3 antagonistsKiller cell immunoglobulin-like receptor 2DL2 antagonists
TargetsKiller cell immunoglobulin-like receptor 2DL1Killer cell immunoglobulin-like receptor 2DL3Killer cell immunoglobulin-like receptor 2DL2
Therapy Area/IndicationsSmoldering Multiple MyelomaUrinary Bladder NeoplasmsBone Marrow Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteBristol Myers Squibb SrlcompanyPrecog Llc
Inactive CompaniesInnate PharmaNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsUrinary Bladder NeoplasmsMultiple MyelomaSquamous Cell Carcinoma of Head and Neck +[5] 
Inactive IndicationsSmoldering Multiple MyelomaBone Marrow NeoplasmsLeukemia, Myeloid, Acute +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG